undamentalytics Newsletter
Sign in

Engene Therapeutics Inc. (ENGN) stock

Add to watchlist

Add holding +

NASDAQ: ENGN Nasdaq Biotechnology Next results ~December 22, 2026

Engene Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in October.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds55 adding, 1 cuttingOf 19 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~December 22, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 10% in the quarter to 2026-07-31.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Engene Therapeutics Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 117% and a beta of 2.1 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
-$0.47 against an average estimate of -$0.43: missed by 10.0%
Share reaction
+1.6% in the first session after the results on September 8, 2026, against -1.0% for the S&P 500
Next report
December 22, 2026; average EPS estimate -$0.46

Engene Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.2%
  • 1 week-8.2%
  • 1 month-25.3%
  • This year-83.9%
  • 1 year-79.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
September 8, 2026
Next results (est.)
December 21, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement
  3. Announcement
  4. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Engene Therapeutics Inc. valuation models and calculator

No model value for Engene Therapeutics Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: December 22, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.46 (range −$0.55 to −$0.37) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.81 +21% — 0%
Next −$1.51 +17% $6m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.8% on 90 days ago. In the last 30 days, 2 analysts raised Engene Therapeutics Inc.'s forecast and 6 cut it.

Consensus EPS forecast Engene Therapeutics Inc., last 90 days
−$2.00 −$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.73 Current fiscal year, 60 days ago: −$1.73 Current fiscal year, 30 days ago: −$1.81 Current fiscal year, 7 days ago: −$1.81 Current fiscal year, Now: −$1.81 −$1.81 Next fiscal year, 90 days ago: −$1.40 Next fiscal year, 60 days ago: −$1.40 Next fiscal year, 30 days ago: −$1.45 Next fiscal year, 7 days ago: −$1.45 Next fiscal year, Now: −$1.51 −$1.51

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.73−$1.40
60 days ago −$1.73−$1.40
30 days ago −$1.81−$1.45
7 days ago −$1.81−$1.45
Now −$1.81−$1.51

Earnings against estimates

Quarter toEstimateActualSurprise
Jul 2026 −$0.43 −$0.47 −10.0%
Apr 2026 −$0.47 −$0.43 +8.6%
Jan 2026 −$0.57 −$0.44 +23.3%
Oct 2025 −$0.58 −$0.73 −26.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Oct 2026
Buy333%
Hold667%
Sell00%

Monthly trend

  1. Oct 20261269
  2. Sep 2026126110
  3. Aug 2026126110
  4. Jul 2026126110

Counts of recommendations published by analysts covering Engene Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.8%
of tradable shares
Days to cover
1.91
at average volume
Short interest, 1 month
+25%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
0.1%
of shares
Employees
81
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
ENGN−11%−28%+36%−84%
Industry peers (median)−18%−29%−5%−26%
S&P 500+26%+25%+18%+11%
Months that ended higher
ENGN83%42%58%55%
S&P 50067%75%75%46%
Largest fall from a high during the year
ENGN−76%−71%−64%−88%
S&P 500−10%−8%−19%−9%

Worst fall since February 1, 2022: 95% from October 27, 2023 to May 12, 2026. Getting back needed a 1875% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.44 – $12.17
From 52-week high
−88.1%
vs 50-day average
−19.1%
vs 200-day average
−66.5%
Volatility (1 year)
117%
Beta vs S&P 500
2.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.2%
After a week
8 up, 4 down
typical move ±7.5%
After a month
7 up, 5 down
typical move ±23.9%
Results releasedNext dayS&P 500 next day5 days21 days
September 8, 2026 +1.6% −1.0% +3.8% −4.1%
June 15, 2026 +8.0% +1.2% +5.6% +18.5%
March 9, 2026 −20.0% +0.7% −16.7% −15.8%
December 22, 2025 +6.1% +1.1% +3.0% +40.0%
September 11, 2025 −9.2% +0.8% +10.7% +33.4%
June 12, 2025 +3.4% −0.7% −2.2% +9.0%
March 10, 2025 −1.9% −3.5% −2.3% −21.5%
December 19, 2024 −1.7% +1.2% +8.3% +22.9%
September 10, 2024 +1.8% +1.5% +5.5% +5.2%
June 14, 2024 −13.5% +0.9% −18.7% −9.3%
March 11, 2024 +4.9% +1.0% +9.6% −1.6%
January 29, 2024 −2.7% +0.7% +3.6% +106.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$66.6M
Institutions reporting
56
Shares held vs prior quarter
▲ 11090.9%
Positions opened / closed
55 / 1

Top buyers and sellers, Q2 2026: 55 institutions bought and 1 sold ; the biggest buyer was Bml Capital Management, LLC (+6.7M shares) and the biggest seller Marshall Wace, LLP (−344K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bml Capital Management, LLC $11.5M 6.7M 17.3% New
Siren, L.L.C. $10.8M 6.3M 16.3% New
Perceptive Advisors LLC $8.3M 4.8M 12.5% New
Ameriprise Financial Inc $4.6M 2.7M 7.0% New
Nextech Invest Ltd. $4M 2.3M 6.0% New
ADAR1 Capital Management, LLC $3.6M 2.1M 5.5% New
Vestal Point Capital, LP $2.9M 1.7M 4.3% New
Acorn Capital Advisors, LLC $2.2M 1.3M 3.3% New
Peapod Lane Capital LLC $1.9M 1.1M 2.9% New
Balyasny Asset Management L.P. $1.7M 1.0M 2.6% New
Millennium Management LLC $1.7M 967K 2.5% New
Renaissance Technologies LLC $1.4M 830K 2.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Engene Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $10,051 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $10,051 net buying
Insider Date Trade Shares Price Value
Grossman William Interim Chief Medical Officer September 22, 2026 Buy 5,102 $1.97 $10,051

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around December 21, 2026 estimated from the company's past filing pattern, not announced

  • September 8, 2026
  • June 15, 2026
  • March 9, 2026
  • December 22, 2025
  • September 11, 2025
  • June 12, 2025

Recent SEC filings

Data status

When each part of this page on Engene Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Engene Therapeutics Inc. in brief

What does Engene Therapeutics Inc. do?
Engene Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in October.
What is Engene Therapeutics Inc.'s stock ticker?
Engene Therapeutics Inc. trades under the ticker ENGN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Engene Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bml Capital Management, LLC, Siren, L.L.C. and Perceptive Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Engene Therapeutics Inc. stock?
Over the last 12 months, Engene Therapeutics Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Engene Therapeutics Inc.'s next earnings date?
Around December 22, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Engene Therapeutics Inc. announces its own schedule.